Continued from here. OK, we’ve run through the key components of the AGI Therapeutics (AGI:ID/LN) offer. You now have a pretty good idea of the terms, attractiveness, timeline and likely success of this deal. But how does it stack up from an investment perspective? Well, as I said, let’s not approach this backwards – as with any investment, no matter your excitement or conviction about the company/stock story, intrinsic valuation comes first:
AGI’s most recent balance sheet (Jun-11) is pretty simple – they’ve $9.251 mio of Cash on hand, while Net Payables of about $0.3 mio are offset by a subsequent sale of patents to Warner Chilcott (WCRX:US) for about $0.3 mio also. This sale probably wiped out some/all of the $0.241 mio in recorded Intangibles, and there’s really nothing else to the B/S. btw I tend to ignore balance sheet Goodwill/Intangibles/etc. anyway when calculating Intrinsic Value. You should be able to confirm/calculate the value of intangibles from other sources – like reserve reports, industry comps, superior/sustainable earnings etc. – if you can’t, it’s usually best to ignore these ‘assets‘ (try tell this to your average junior resource company investor, sigh…).